COMMUNIQUÉS West-GlobeNewswire

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
06/06/2025
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England [...]
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
06/06/2025
SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
06/06/2025
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its [...]
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
06/06/2025
ORLADEYO® (berotralstat) now reimbursed in the Netherlands RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive [...]
Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression
06/06/2025
- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104 (liafensine) in treatment- [...]
Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025
06/06/2025
Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD) PFM improved inorganic pyrophosphate (PPi) efflux via on [...]
Polpharma Group soutient l’action urgente de l’UE visant à garantir l’accès aux médicaments et à renforcer la souveraineté pharmaceutique européenne
06/06/2025
En tant que membre de l’association Medicines for Europe, Polpharma Group se joint aux leaders du secteur pour appeler les Premiers ministres de l’UE à adopter un plan d’action pharmaceutique en cinq points destiné à [...]
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
06/06/2025
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( [...]
Burning Rock Reports First Quarter 2025 Financial Results
06/06/2025
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the [...]
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
06/06/2025
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. [...]
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative
06/06/2025
Press Release Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative June 6, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA ( [...]
Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 juin 2025 et désignation d’un mandataire ad hoc
06/06/2025
Communiqué de presse Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 27 juin 2025 et désignation d’un mandataire ad hoc 6 juin 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models
06/06/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Idorsia publishes invitations to bondholder meetings
06/06/2025
Ad hoc announcement pursuant to Art. 53 LR Bondholder meetings will take place on Wednesday, June 25, 2025, to vote on proposals to amend the terms of the two outstanding convertible bonds CB 2025 and CB 2028 Allschwil [...]
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
06/06/2025
Total gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants [...]
Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes
05/06/2025
CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced it has priced an offering (the “Offering”) of $550 million aggregate principal [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/06/2025
BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention [...]
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
05/06/2025
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]
ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)
05/06/2025
– Previously inoperable patient converted to eligible for resection, underwent pancreaticoduodenectomy, following single course of treatment with Padeliporfin VTP – TEL AVIV, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- [...]

Pages